一分钟看懂
这是一项关于乳腺癌的II 期研究，登记的药物或干预包括Neratinib；Trastuzumab Deruxtecan，当前状态为招募中。登记地点显示中国上海有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Neratinib；Trastuzumab Deruxtecan · II 期
登记条件中文摘要
年龄范围：18岁至70岁
登记的基本范围为女性，年龄18岁至70岁；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Fudan University Shanghai Cancer Center · 上海
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- Participants must meet all of the following inclusion criteria in order to be enrolled in this study:
- 1. Female, aged 18-70 years old.
- 2. ECOG score ranges from 0 to 1.
- 3. Expected survival period is greater than 12 weeks.
- 4. Histologically confirmed invasive HER2 positive breast cancer (HER2 IHC+++or FISH/CISH positive, all samples need to be verified by the pathology department of the research center).
- 5. Tumor staging: recurrent or metastatic breast cancer; Patients with local recurrence need to be confirmed by the researcher that radical surgical resection cannot be performed.
- 6. The subject has at least one lesion (measurable and/or unmeasurable) that has not received radiation therapy in the past.
- 7. MRI or CT shows brain metastasis and meets one of the following conditions:
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07152782；登记信息更新于 2026-09-28；本站同步于 2026-10-08。